Wu 1993.

Methods	Multi‐centre study (Taiwan). Open label Method of randomization: NR Concealment of allocation: NR Duration of treatment: single dose Follow‐up: 2 h
Participants	64 patients with high blood pressure and cerebral signs or symptoms symptoms (headache, dizziness, convulsion, coma) during haemodyalisis. Inclusion Criteria: Patients with SBP >190 or DBP >120 associated with symptoms (headache, dizziness, convulsion, coma) during haemodyalisis. Exclusion Criteria: Patients with increasing BP less than 20 min after initiating haemodyalisis. Patients with drop of BP to level less than 170/110 within 20 min were also excluded. * Except for BP and HR, baseline characteristics were not provided. The type of emergencies was not reported according to randomized group.
Interventions	Nifedipine (N):n=30, Captopril (C): n=35 Prazosin (P):n=27 Dose regimen: sublingual single dose Nifedipine 10 mg , Captopril 25 mg , and Prazosin 10 mg
Outcomes	Outcomes obtained from this trial: Total SAE: Not reported (NR) Mortality: NR Total non‐fatal cardiovascular events: NR Individual CVE: NR Withdraw due to adverse events= N/A (single dose) Blood pressure: Data was obtained from tables 1,2 and 3 on page 285‐286. Standard deviation of change was not reported but imputed from end point. The calculated weighted mean BP change was: Captopril: SBP‐41±8, DBP‐27.71±10 Nifedipine: SBP‐42±10, DBP‐35.85±8 Prazosin: SBP‐14.6±6, DBP‐21.57±8 Heart rate: Data was obtained from tables 1,2 and 3 on page 285‐286. Standard deviation of change was not reported but imputed from end point. The calculated weighted mean HR change was: Captopril: ‐1.28±9 Nifedipine: ‐4.28±17 Prazosin: ‐0.85±9
Notes	Source of Funding : NR
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear